Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT-Stromal and Tgfß-Dependent Mechanisms.
Mol Cancer Ther
; 21(11): 1729-1741, 2022 11 03.
Article
em En
| MEDLINE
| ID: mdl-36129800
SIGNIFICANCE: Most patients with bladder cancer do not respond to ICB targeting of the PD-L1 signaling axis. Our modeling applied a de novo resistance signature to show that tumor-infiltrating myeloid cells promote poor treatment response in a TGFß-dependent mechanism.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Bexiga Urinária
/
Antígeno B7-H1
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article